Advertisement

Supportive Care in Cancer

, Volume 3, Issue 3, pp 194–197 | Cite as

A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour

  • P. Lissoni
  • S. Barni
  • V. Fossati
  • A. Ardizzoia
  • M. Cazzaniga
  • G. Tancini
  • F. Frigerio
Original Article

Abstract

Recent advances in our knowledge of psychoneuroimmune interactions involved in the control of tumour growth have shown the possibility of manipulating host anticancer defences through a neuroimmunotherapeutic strategy. In particular, our previous studies have demonstrated that the concomitant administration of the pineal neurohormone melatonin may amplify the antitumour efficacy of interleukin-2 (IL-2) in humans. On this basis, a study was planned to investigate the influence of neuroimmunotherapy with low-dose IL-2 plus melatonin on survival time and on performance status in untreatable metastatic cancer patients. The study included 100 patients with metastatic solid tumours, for whom no standard therapy was available. They were randomized to receive IL-2 (3 x 106 IU/day subcutaneously for 4 weeks) plus melatonin (40 mg/day orally) or supportive care alone. Partial tumour regressions were seen in 9/52 (17%) patients treated with the immunotherapy, and in none of the patients treated with supportive care alone. The percentage of survival at 1 year was significantly higher in patients treated with IL-2 and melatonin than in those receiving the supportive care alone (21/52 versus 5/48, P<0.005). Moreover, the performence status improved in 22/52 patients of the immunotherapy group and in only 8.48 patients treated with supportive care (P<0.01). This study shows that cancer neuroimmunotherapy with low-dose IL-2 and the pineal hormone melatonin may prolong the survival time and improve the quality of life of patients with metastatic solid tumours who do not respond to conventional therapies.

Key words

Immunotherapy Interleukin-2 Melatonin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Atzpodien J, Kirchner H (1990) Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68:1–11Google Scholar
  2. 2.
    Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2β in advanced human malignancies. Lancet I:1509–1512Google Scholar
  3. 3.
    Chouaib S, Fradelizi D (1982) The mechanism of inhibition of human IL 2 production. J Immunol 129:2463–2467Google Scholar
  4. 4.
    Lissoni P, Barni S, Paolorossi F, et al (1987) Evidence for altered opioid activity in patients with cancer. Br J Cancer 56:834–837Google Scholar
  5. 5.
    Lissoni P, Barni S, Archili C, et al (1990) Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. Anticancer Res 10:753–758Google Scholar
  6. 6.
    Lissoni P, Barni S, Tancini G, et al (1994) A randomized study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69:196–199Google Scholar
  7. 7.
    Maestroni GJM, Conti A, Pierpaoli W (1986) Role of the pineal gland in immunity. J Neuroimmunol 13:19–26Google Scholar
  8. 8.
    Plotnikoff NP, Miller GC (1983) Enkephalins as immunomodulators. Int J Immunopharmacol 5:437–442Google Scholar
  9. 9.
    Regelson W, Pierpaoli W (1987) Melatonin: a rediscovered antitumor hormone? Cancer Invest 5:379–385Google Scholar
  10. 10.
    Rosenberg SA, Lotze MT, Muul LM, et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897Google Scholar
  11. 11.
    Stein RC, Malkovska V, Morgan S, et al (1991) The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. Br J Cancer 63:275–278Google Scholar
  12. 12.
    Wanebo HJ, Pace R, Hargett S, Katz D, Sando J (1986) Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer 57:656–662Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • P. Lissoni
    • 1
  • S. Barni
    • 1
  • V. Fossati
    • 1
  • A. Ardizzoia
    • 1
  • M. Cazzaniga
    • 1
  • G. Tancini
    • 1
  • F. Frigerio
    • 1
  1. 1.Divisione di RadioterapiaOspedale S. GerardoMonza (Milan)Italy

Personalised recommendations